



PATENT 0020-4872P

### IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Kyogo ITOH et al. Conf.:

Appl. No.:

09/857,308

Group:

1642

Filed:

June 1, 2001

Examiner: C. Yaen

For:

NOVEL TUMOR ANTIGEN PROTEIN ART-1 AND

TUMOR ANTIGEN PEPTIDES THEREOF

### LARGE ENTITY TRANSMITTAL FORM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 September 1, 2004

#### Sir:

Transmitted herewith is a Reply in the above-identified application.

The enclosed	document	is	being	transm	itted	via	the	Certificate
of Mailing p	rovisions	of	37 C.	F.R. §	1.8.			

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	30	-	44	=	0	\$ 18	\$0.00
INDEPENDENT	1	_	3	=	0	\$ 86	\$0.00
FIRST PRESEN	\$290	\$0.00					
						TOTAL	\$0.00

	Petition for () mor 37 C.F.R. §§ 1.17 and 1. time.		<del>-</del>
$\boxtimes$	No fee is required.		
	Check(s) in the amount of	is(are)	enclosed.
	Please charge Deposit Acc \$0.00. This form is submi		

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

John W. Bailev, #32,881

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

/// JWB/KLR:gmh 0020-4872P

Attachment(s)

(Rev. 09/30/03)



PATENT 0020-4872P

#### IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Kyogo ITOH et al.

Conf.: 3463

Appl. No.:

09/857,308

Group:

1642

Filed:

June 1, 2001

Examiner: YAEN, C.

For:

NOVEL TUMOR ANTIGEN PROTEIN ART-1 AND

TUMOR ANTIGEN PEPTIDES THEREOF

# REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

September 1, 2004

## Sir:

In reply to the Office Action dated June 1, 2004, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.